Found: 4
Select item for more details and to access through your institution.
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2-Advanced Breast Cancer.
- Published in:
- Current Oncology, 2021, v. 28, n. 1, p. 491, doi. 10.3390/curroncol28010051
- By:
- Publication type:
- Article
Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S311, doi. 10.1016/j.clml.2017.07.111
- By:
- Publication type:
- Article
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 1045, doi. 10.1007/s40273-021-01027-4
- By:
- Publication type:
- Article
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
- Published in:
- 2021
- By:
- Publication type:
- journal article